Treatment of advanced and recurrent squamous carcinoma of the uterine cervix with constant intraarterial infusion of cisplatin

M. A. Rettenmaier, M. F. Moran, N. F. Ramsinghani, M. Colman, N. A. Syed, A. Puthawala, F. W. Jansen, P. J. Disaia

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Twelve patients with primary or locally recurrent squamous carcinoma of the cervix were treated with constant internal iliac artery infusion of cisplatin (CDDP) via a totally implantable chemotherapy pump. Seven previously untreated patients received standard external and interstitial radiotherapy (RT) in conjunction with CDDP infusion. Five patients with isolated pelvic recurrences received CDDP therapy only. The chemotherapy pump was refilled weekly on an outpatient basis. All nine evaluable patients developed unilateral or bilateral lower extremity pain which responded to dosage reduction. No renal or marrow toxicity was seen. Both of the evaluable patients treated for recurrent tumor died 32 and 60 weeks after initiation of treatment. The seven patients treated with RT + CDDP infusion include one who expired with persistent tumor and one with no evidence of disease (NED) after exenteration for a pelvic recurrence at 48 and 85 weeks respectively. The five remaining patients are NED at 12 to 60 weeks. Constant internal iliac artery infusion of CDDP via an implantable chemotherapy pump can be performed with acceptable toxicity. The preliminary results suggest that further study in previously untreated undergoing concurrent radiotherapy is warranted.

Original languageEnglish (US)
Pages (from-to)1301-1303
Number of pages3
JournalCancer
Volume61
Issue number7
StatePublished - 1988
Externally publishedYes

Fingerprint

Intra Arterial Infusions
Cervix Uteri
Cisplatin
Squamous Cell Carcinoma
Iliac Artery
Drug Therapy
Therapeutics
Radiotherapy
Pelvic Exenteration
Recurrence
Brachytherapy
Lower Extremity
Neoplasms
Outpatients
Bone Marrow
Kidney
Pain

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Rettenmaier, M. A., Moran, M. F., Ramsinghani, N. F., Colman, M., Syed, N. A., Puthawala, A., ... Disaia, P. J. (1988). Treatment of advanced and recurrent squamous carcinoma of the uterine cervix with constant intraarterial infusion of cisplatin. Cancer, 61(7), 1301-1303.

Treatment of advanced and recurrent squamous carcinoma of the uterine cervix with constant intraarterial infusion of cisplatin. / Rettenmaier, M. A.; Moran, M. F.; Ramsinghani, N. F.; Colman, M.; Syed, N. A.; Puthawala, A.; Jansen, F. W.; Disaia, P. J.

In: Cancer, Vol. 61, No. 7, 1988, p. 1301-1303.

Research output: Contribution to journalArticle

Rettenmaier, MA, Moran, MF, Ramsinghani, NF, Colman, M, Syed, NA, Puthawala, A, Jansen, FW & Disaia, PJ 1988, 'Treatment of advanced and recurrent squamous carcinoma of the uterine cervix with constant intraarterial infusion of cisplatin', Cancer, vol. 61, no. 7, pp. 1301-1303.
Rettenmaier MA, Moran MF, Ramsinghani NF, Colman M, Syed NA, Puthawala A et al. Treatment of advanced and recurrent squamous carcinoma of the uterine cervix with constant intraarterial infusion of cisplatin. Cancer. 1988;61(7):1301-1303.
Rettenmaier, M. A. ; Moran, M. F. ; Ramsinghani, N. F. ; Colman, M. ; Syed, N. A. ; Puthawala, A. ; Jansen, F. W. ; Disaia, P. J. / Treatment of advanced and recurrent squamous carcinoma of the uterine cervix with constant intraarterial infusion of cisplatin. In: Cancer. 1988 ; Vol. 61, No. 7. pp. 1301-1303.
@article{b6d779cb4f4a44fbbc6fdfa4005619b2,
title = "Treatment of advanced and recurrent squamous carcinoma of the uterine cervix with constant intraarterial infusion of cisplatin",
abstract = "Twelve patients with primary or locally recurrent squamous carcinoma of the cervix were treated with constant internal iliac artery infusion of cisplatin (CDDP) via a totally implantable chemotherapy pump. Seven previously untreated patients received standard external and interstitial radiotherapy (RT) in conjunction with CDDP infusion. Five patients with isolated pelvic recurrences received CDDP therapy only. The chemotherapy pump was refilled weekly on an outpatient basis. All nine evaluable patients developed unilateral or bilateral lower extremity pain which responded to dosage reduction. No renal or marrow toxicity was seen. Both of the evaluable patients treated for recurrent tumor died 32 and 60 weeks after initiation of treatment. The seven patients treated with RT + CDDP infusion include one who expired with persistent tumor and one with no evidence of disease (NED) after exenteration for a pelvic recurrence at 48 and 85 weeks respectively. The five remaining patients are NED at 12 to 60 weeks. Constant internal iliac artery infusion of CDDP via an implantable chemotherapy pump can be performed with acceptable toxicity. The preliminary results suggest that further study in previously untreated undergoing concurrent radiotherapy is warranted.",
author = "Rettenmaier, {M. A.} and Moran, {M. F.} and Ramsinghani, {N. F.} and M. Colman and Syed, {N. A.} and A. Puthawala and Jansen, {F. W.} and Disaia, {P. J.}",
year = "1988",
language = "English (US)",
volume = "61",
pages = "1301--1303",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Treatment of advanced and recurrent squamous carcinoma of the uterine cervix with constant intraarterial infusion of cisplatin

AU - Rettenmaier, M. A.

AU - Moran, M. F.

AU - Ramsinghani, N. F.

AU - Colman, M.

AU - Syed, N. A.

AU - Puthawala, A.

AU - Jansen, F. W.

AU - Disaia, P. J.

PY - 1988

Y1 - 1988

N2 - Twelve patients with primary or locally recurrent squamous carcinoma of the cervix were treated with constant internal iliac artery infusion of cisplatin (CDDP) via a totally implantable chemotherapy pump. Seven previously untreated patients received standard external and interstitial radiotherapy (RT) in conjunction with CDDP infusion. Five patients with isolated pelvic recurrences received CDDP therapy only. The chemotherapy pump was refilled weekly on an outpatient basis. All nine evaluable patients developed unilateral or bilateral lower extremity pain which responded to dosage reduction. No renal or marrow toxicity was seen. Both of the evaluable patients treated for recurrent tumor died 32 and 60 weeks after initiation of treatment. The seven patients treated with RT + CDDP infusion include one who expired with persistent tumor and one with no evidence of disease (NED) after exenteration for a pelvic recurrence at 48 and 85 weeks respectively. The five remaining patients are NED at 12 to 60 weeks. Constant internal iliac artery infusion of CDDP via an implantable chemotherapy pump can be performed with acceptable toxicity. The preliminary results suggest that further study in previously untreated undergoing concurrent radiotherapy is warranted.

AB - Twelve patients with primary or locally recurrent squamous carcinoma of the cervix were treated with constant internal iliac artery infusion of cisplatin (CDDP) via a totally implantable chemotherapy pump. Seven previously untreated patients received standard external and interstitial radiotherapy (RT) in conjunction with CDDP infusion. Five patients with isolated pelvic recurrences received CDDP therapy only. The chemotherapy pump was refilled weekly on an outpatient basis. All nine evaluable patients developed unilateral or bilateral lower extremity pain which responded to dosage reduction. No renal or marrow toxicity was seen. Both of the evaluable patients treated for recurrent tumor died 32 and 60 weeks after initiation of treatment. The seven patients treated with RT + CDDP infusion include one who expired with persistent tumor and one with no evidence of disease (NED) after exenteration for a pelvic recurrence at 48 and 85 weeks respectively. The five remaining patients are NED at 12 to 60 weeks. Constant internal iliac artery infusion of CDDP via an implantable chemotherapy pump can be performed with acceptable toxicity. The preliminary results suggest that further study in previously untreated undergoing concurrent radiotherapy is warranted.

UR - http://www.scopus.com/inward/record.url?scp=0023837648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023837648&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 1301

EP - 1303

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -